500
Participants
Start Date
March 22, 2022
Primary Completion Date
December 1, 2024
Study Completion Date
March 1, 2025
Multiparametric MRI +/- prostate biopsy
MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings
Biparametric MRI +/- prostate biopsy
MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings
NYU Langone, New York
Icahn School of Medicine (Mount Sinai), New York
New York Presbyterian Hospital, New York
Mayo Clinic, Rochester
Centro de Urologia, Buenos Aires
Monash University, Melbourne
Peter MacCallum Cancer Centre, Melbourne E.
Ghent University Hospital, Ghent
Hospital Sírio-Libanês, São Paulo
Princess Margaret Cancer Centre, Toronto
Herlev and Gentofte Hospital, Copenhagen
Helsinki University Hospital, Helsinki
Bordeaux Pellegrin University Hospital, Bordeaux
CHU Lille, Lille
Sorbonne Université, Paris
Heinrich Heine University Düsseldorf, Düsseldorf
Essen University Hospital, Essen
University Hospital Frankfurt, Frankfurt
Martini Klinik, Hamburg
San Raffaele Hospital, Milan
Sapienza University, Rome
San Giovanni Battista Hospital, Turin
University Hospital of Udine, Udine
Radboudumc, Nijmegen
Tan Tock Seng Hospital, Novena
Hospital Universitario Reina Sofía, Córdoba
Hospital Universitario La Moraleja, Madrid
Addenbrooke's Hospital, Cambridge
Royal Free London NHS Foundation Trust, London
University College London and University College London Hospital, London
Whittington Hospital, London
University College, London
OTHER